LON:ONC Oncimmune Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 87.50 0.00 (0.00%) (As of 07/4/2022 12:00 AM ET) Add Compare Share Today's Range 85.68▼ 87.5050-Day Range 85.34▼ 121.5052-Week Range 85.34▼ 195Volume776 shsAverage Volume52,250 shsMarket Capitalization£60.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlines Oncimmune MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.22 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Oncimmune. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for ONC. Previous Next 0.0 Dividend Strength Dividend YieldOncimmune does not currently pay a dividend.Dividend GrowthOncimmune does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONC. Previous Next 1.1 News and Social Media Coverage News SentimentOncimmune has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncimmune insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncimmune is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncimmune is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncimmune has a P/B Ratio of 48.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address About Oncimmune (LON:ONC) StockOncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.Read More ONC Stock News HeadlinesJune 22, 2022 | americanbankingnews.comOncimmune (LON:ONC) Hits New 12-Month Low at $86.20June 16, 2022 | finance.yahoo.comFurther weakness as Oncimmune Holdings (LON:ONC) drops 12% this week, taking one-year losses to 56%June 2, 2022 | benzinga.comGlobal Cancer Biopsy Market to Reach USD 43,692 Million | Growing at CAGR of 10.7% | Insights and Tools and Forecast 2028April 21, 2022 | proactiveinvestors.com.auOncimmune receives 2022 Queen's Award for EnterpriseApril 8, 2022 | proactiveinvestors.com.auFTSE 100 ends the week higher as Wall Street also recoversApril 8, 2022 | proactiveinvestors.comFTSE follows US rally while Elon Musk faces potential SEC probe and UK starting salaries riseApril 8, 2022 | lse.co.ukOncimmune agrees two new commercial contractsMarch 7, 2022 | proactiveinvestors.com.auOncimmune lands follow-on Covid study contractMarch 7, 2022 | marketwatch.comOncimmune Holdings Wins Follow-On Contract for Covid-19 StudyFebruary 28, 2022 | marketwatch.comOncimmune 1H Pretax Loss Widened as Covid-19 Restrictions EaseFebruary 28, 2022 | morningstar.comOncimmune Signs Contract With Verily Life Sciences to Investigate Long-CovidFebruary 17, 2022 | marketwatch.comOncimmune Holdings's Lung Blood Test to Be Used in Spanish RegionFebruary 17, 2022 | proactiveinvestors.comOncimmune lung cancer diagnostic receives regulatory green light from second Spanish regional health authorityJanuary 4, 2022 | markets.businessinsider.comOncimmune Hldgs PLC : Results from COVID-19 autoantibody profiling panelDecember 31, 2021 | lse.co.ukOncimmune study suggests antibodies spike following Covid infectionDecember 26, 2021 | markets.businessinsider.comOncimmune Hldngs PLC : Grant of Options and PDMR DealingDecember 22, 2021 | markets.businessinsider.comOncimmune Hldngs PLC : ImmunoINSIGHTS commercial updateDecember 22, 2021 | markets.businessinsider.comOncimmune Hldngs PLC : PDMR DealingDecember 21, 2021 | lse.co.ukOncimmune shares up after multiple commercial contract winsDecember 21, 2021 | marketwatch.comOncimmune Signs Deal With Major Pharma Company to Provide Autoantibody Biomarker ServicesDecember 7, 2021 | marketwatch.comOncimmune Holdings Says ImmunoInsights' 2Q Was Best to Date For Contract WinsNovember 6, 2021 | markets.businessinsider.comOncimmune Hldngs PLC : Notice of Full Year resultsNovember 2, 2021 | lse.co.ukAIM WINNERS & LOSERS: Warpaint sees profit topping market forecastsNovember 2, 2021 | marketwatch.comOncimmune Shares Fall After FY 2021 Revenue Missed GuidanceOctober 29, 2021 | lse.co.ukEXECUTIVE CHANGES: TP chair resigns amid pressure from Science GroupSee More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:ONC CUSIPN/A CIKN/A Weboncimmune.com Phone+44-115-8231869FaxN/AEmployees52Year FoundedN/ACompany Calendar Last Earnings2/13/2018Today7/04/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio0.34 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio677.62 Current Ratio1.08 Quick Ratio1.04 Sales & Book Value Annual Sales£3.33 million Price / Sales18.28 Cash FlowGBX 4.39 per share Price / Cash Flow19.94 Book ValueGBX 1.80 per share Price / Book48.61Miscellaneous Outstanding Shares69,475,000Free FloatN/AMarket Cap£60.79 million OptionableNot Optionable BetaN/A Oncimmune Frequently Asked Questions How has Oncimmune's stock price performed in 2022? Oncimmune's stock was trading at GBX 175 at the beginning of 2022. Since then, ONC stock has decreased by 50.0% and is now trading at GBX 87.50. View the best growth stocks for 2022 here. How were Oncimmune's earnings last quarter? Oncimmune Holdings plc (LON:ONC) released its earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share for the quarter. The business earned $0.08 million during the quarter. View Oncimmune's earnings history. Who are Oncimmune's key executives? Oncimmune's management team includes the following people: Dr. Adam Mark Hill Ph.D., CEO & Director (Age 42, Pay $439k)Mr. Matthew Hall, Chief Financial OfficerProf. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Chief Scientific OfficerMs. Cléa Rosenfeld, Head of Investor RelationsMr. Ron Kirschner, Gen. Counsel & Company Sec.Dr. James R. Jett M.D., Chief Medical Officer of USMr. Maarten Brusse, Chief Commercial Officer of AsiaMr. Shane Smith, Sr. VP of Market Access & Reimbursement Oncimmune (Usa)Mr. Cameron Barnard, Chief Bus. OfficerMr. Andrew Millet BA, FCA, MBA, Exec. (Age 55) Who are some of Oncimmune's key competitors? Some companies that are related to Oncimmune include Profound Medical (PRN), Profound Medical (PRN), Renalytix (RENX), Akumin (AKU), SQI Diagnostics (SQD), Yourgene Health (YGEN), VentriPoint Diagnostics (VPT), Verici Dx (VRCI), Cambridge Cognition (COG), GeneNews (GEN), LexaGene (LXG), genedrive (GDR), GENinCode (GENI), LED Medical Diagnostics (LMD) and Abingdon Health (ABDX). View all of ONC's competitors. What other stocks do shareholders of Oncimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), (APHA), (AQB), Axsome Therapeutics (AXSM), (BGSF), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST). What is Oncimmune's stock symbol? Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC." How do I buy shares of Oncimmune? Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Oncimmune's stock price today? One share of ONC stock can currently be purchased for approximately GBX 87.50. How much money does Oncimmune make? Oncimmune (LON:ONC) has a market capitalization of £60.79 million and generates £3.33 million in revenue each year. How many employees does Oncimmune have? Oncimmune employs 52 workers across the globe. How can I contact Oncimmune? Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The official website for Oncimmune is oncimmune.com. The company can be reached via phone at +44-115-8231869. This page (LON:ONC) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
